Amarin Corporation PLC (NASDAQ:AMRN) has been given a consensus rating of “Hold” by the six brokerages that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $10.00.

A number of brokerages have weighed in on AMRN. ValuEngine raised Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research downgraded Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Amarin Corporation PLC in a research report on Thursday, November 2nd. Cantor Fitzgerald set a $10.00 price target on Amarin Corporation PLC and gave the stock a “buy” rating in a research report on Wednesday, November 1st. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of Amarin Corporation PLC in a research report on Wednesday, October 11th.

TRADEMARK VIOLATION WARNING: “Brokerages Set Amarin Corporation PLC (AMRN) Price Target at $8.00” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/brokerages-set-amarin-corporation-plc-amrn-price-target-at-8-00/1686295.html.

Shares of Amarin Corporation PLC (NASDAQ AMRN) traded down $0.10 during midday trading on Thursday, reaching $3.56. The company’s stock had a trading volume of 902,916 shares, compared to its average volume of 1,290,000. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63. Amarin Corporation PLC has a 1 year low of $2.81 and a 1 year high of $4.47.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. Amarin Corporation PLC’s quarterly revenue was up 45.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.08) EPS. analysts anticipate that Amarin Corporation PLC will post -0.21 earnings per share for the current fiscal year.

In other news, insider Steven B. Ketchum sold 63,479 shares of the company’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.72% of the stock is currently owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Renaissance Technologies LLC grew its position in Amarin Corporation PLC by 348.2% during the first quarter. Renaissance Technologies LLC now owns 1,730,200 shares of the biopharmaceutical company’s stock worth $5,537,000 after buying an additional 1,344,200 shares in the last quarter. Morgan Stanley grew its position in Amarin Corporation PLC by 119.7% during the first quarter. Morgan Stanley now owns 1,138,992 shares of the biopharmaceutical company’s stock worth $3,645,000 after buying an additional 620,577 shares in the last quarter. UBS Group AG grew its position in Amarin Corporation PLC by 7.4% during the first quarter. UBS Group AG now owns 731,518 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 50,200 shares in the last quarter. California Public Employees Retirement System grew its position in Amarin Corporation PLC by 13.3% during the first quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company’s stock worth $1,707,000 after buying an additional 62,800 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its position in Amarin Corporation PLC by 0.9% during the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock worth $1,266,000 after buying an additional 3,413 shares in the last quarter. 37.65% of the stock is currently owned by institutional investors and hedge funds.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.